FDA panel unanimously backs Onyx cancer drug

(AP) — A federal panel of cancer specialists on Wednesday unanimously recommended approval of an experimental drug from Onyx Pharmaceuticals Inc. for patients with advanced blood cancer.

The U.S. Food and Drug Administration panel voted 11-0, with one abstention, in favor of carfilzomib as a treatment for with advanced forms of multiple myeloma that hasn't responded to other drugs.

The FDA is not required to follow the group's advice but often does. A final decision is expected by July 27.

In documents posted earlier this week, FDA scientists raised safety concerns about carfilzomib, including toxic side effects on the heart and lungs. They also questioned the injectable drug's effectiveness.

Onyx studied the drug in 266 patients who had already been treated with two other drugs. About 22 percent of patients studied responded to the drug, with the typical patient surviving slightly less than eight months after beginning treatment. In its briefing, the FDA panel commented that the response rate was so low "it may not provide an advantage over available therapy."

But FDA's panelists said the drug could still be an important treatment for patients with few other options. The FDA has approved seven drugs for multiple myeloma. Doctors use different therapies depending on a patient's age and health and stage of disease.

Over 50,000 people have multiple myeloma in the U.S., and about 20,000 new cases are diagnosed annually.

If approved, Onyx would market the under the brand name Kyprolis.

South San Francisco-based Onyx said in a statement that the vote "is an important regulatory milestone in the review of Kyprolis, and we are committed to working with the FDA to bring this treatment to patients as quickly as possible."

Company shares fell 9 cents to $44.49 in afterhours trading Wednesday. Shares rose 32 cents to $44.58 in regular trading before being halted ahead of the panel vote.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US focuses on toxic side effects with Onyx drug

Jun 18, 2012

(AP) — The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments